Skip to main content

Table 3 Association of rs9939609 with anthropometric, clinical, inflammation and CVD risk biomarkers in children

From: Influence of FTO variants on obesity, inflammation and cardiovascular disease risk biomarkers in Spanish children: a case–control multicentre study

Biomarkers TT AT AA β (95% CI) P Pa
n 162 267 102    
Anthropometric factors  
Height (m) 1.38 ± 0.01 1.39 ± 0.01 1.40 ± 0.02 −0.003 (−0.01, 0.00) 0.148 0.594
Weight (kg) 42.3 ± 1.4 45.6 ± 1.1 50.1 ± 2.2 3.31 (1.52, 5.10) 0.001 0.397
BMI (kg/m2) 21.69 ± 0.48 22.89 ± 0.36 24.51 ± 0.64 1.32 (0.59, 2.05) 0.001 --
BMI z-score 1.48 ± 0.16 1.86 ± 0.13 2.32 ± 0.22 0.45 (0.19, 0.71) 0.001 --
Waist circumference (cm) 70.58 ± 1.39 72.85 ± 0.99 77.46 ± 1.71 3.35 (0.61, 6.10) 0.017 0.487
Clinical and metabolic biomarkers  
Systolic BP (mm Hg) 104 ± 1 104 ± 1 107 ± 1 1.14 (−0.71, 2.99) 0.227 0.466
Diastolic BP (mm Hg) 63 ± 1 65 ± 1 66 ± 1 1.24 (−0.26, 2.74) 0.106 0.888
Glucose (mg/dl) 85 ± 1 84 ± 0 84 ± 1 −0.47 (−1.34, 0.39) 0.286 0.143
Insulin (mU/l) 8.82 ± 0.64 8.73 ± 0.43 9.78 ± 0.71 0.02 (−0.01, 0.05) 0.253 0.225
HOMA-IR 1.89 ± 0.15 1.85 ± 0.10 2.07 ± 0.16 0.02 (−0.02, 0.05) 0.345 0.181
Triacylglycerols (mg/dl) 67 ± 3 64 ± 2 68 ± 4 0.07 (−3.90, 4.03) 0.974 0.216
ApoAI (mg/dl) 142 ± 2 141 ± 2 135 ± 3 −3.01 (−6.36, 0.34) 0.079 0.457
Cholesterol (mg/dl) 169 ± 3 166 ± 2 170 ± 2 0.002 (−0.01, 0.01) 0.721 0.540
HDL-c (mg/dl) 57 ± 1 57 ± 1 55 ± 1 −0.94 (−2.76, 0.89) 0.316 0.509
Adiponectin (mg/l) 25.89 ± 0.95 25.13 ± 0.74 24.16 ± 1.10 −0.72 (−2.18, 0.73) 0.331 0.934
Resistin (μg/l) 10.33 ± 0.44 10.81 ± 0.35 11.43 ± 0.55 0.55 (−0.15, 1.25) 0.125 0.384
Leptin (μg/l) 13.57 ± 1.23 14.37 ± 0.83 16.29 ± 1.52 1.38 (−0.43, 3.18) 0.135 0.149
Inflammatory biomarkers  
C-reactive protein (mg/l) 2.08 ± 0.29 2.21 ± 0.23 2.77 ± 0.53 0.37 (−0.14, 0.88) 0.153 0.743
IL-6 (ng/l) 5.61 ± 0.90 6.00 ± 0.69 6.19 ± 1.05 0.42 (−0.96, 1.80) 0.550 0.759
IL-8 (ng/l) 1.86 ± 0.16 1.95 ± 0.15 1.83 ± 0.21 0.03 (−0.25, 0.30) 0.853 0.783
TNF-α (ng/l) 3.53 ± 0.16 3.66 ± 0.13 3.33 ± 0.20 −0.02 (−0.27, 0.23) 0.875 0.308
Cardiovascular disease risk biomarkers  
MMP-9 (μg/l) 80.39 ± 4.35 83.62 ± 3.70 92.82 ± 6.05 0.03 (0.00, 0.07) 0.049 0.048
MPO (μg/l) 17.56 ± 2.06 17.84 ± 1.61 17.65 ± 1.88 0.29 (−2.80, 3.38) 0.853 0.636
sE-Selectin (μg/l) 26.34 ± 1.14 28.22 ± 1.05 26.64 ± 1.40 0.66 (−1.25, 2.56) 0.500 0.711
sICAM-1 (mg/l) 0.162 ± 0.005 0.168 ± 0.004 0.158 ± 0.006 0.001 (−0.01, 0.01) 0.997 0.645
Active PAI-1 (μg/l) 8.35 ± 0.58 8.61 ± 0.52 10.35 ± 0.97 0.85 (−0.19, 1.89) 0.109 0.946
Total PAI-1 (μg/l) 23.22 ± 1.34 22.21 ± 0.92 26.84 ± 2.09 0.02 (−0.02, 0.06) 0.359 0.994
  1. CI: Confidence interval; BMI: body mass index; BP: blood pressure; HOMA-IR: homeostasis model assessment for insulin resistance; HDL-c: high-density lipoprotein cholesterol; IL: interleukin; TNF-α: tumour necrosis factor alpha; MMP-9: matrix metalloproteinase-9; MPO: myeloperoxidase; sICAM-1: soluble intracellular adhesion molecule-1, PAI-1: plasminogen activator inhibitor. β Coefficients represent the change in absolute traits values of each additional risk allele. General linear models were used to examine associations, P adjusted by age and sex, Pa adjusted by age, sex, and BMI.
\